EXCLUSIVE: BioRestorative Therapies Tells Benzinga Co Receives License From New York State Department Of Health To Act As Tissue Bank For Mesenchymal Stem Cell Processing
Portfolio Pulse from Benzinga Newsdesk
BioRestorative Therapies has received a license from the New York State Department of Health to act as a tissue bank for mesenchymal stem cell processing.

May 31, 2023 | 10:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioRestorative Therapies' license from the NY State Department of Health to process mesenchymal stem cells may boost its position in the stem cell market.
The license from the New York State Department of Health allows BioRestorative Therapies to process mesenchymal stem cells, which could lead to new opportunities and partnerships in the stem cell market. This may positively impact the company's stock price in the short term as it demonstrates regulatory approval and potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100